Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 13/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30907378 | 0.93 | GSK3B (0.42) | GSK3BDYRK1AABL1MAP4K1AAK1 | |
| SCHEMBL30907652 | 0.88 | GSK3B (0.47) | GSK3BDYRK1AABL1MAP4K1AAK1 | |
| SCHEMBL30907111 | 0.87 | ABL1 (0.43) | ABL1 | |
| SCHEMBL30907366 | 0.84 | ABL1 (0.44) | GSK3BDYRK1AABL1MAP4K1SREBF2 | |
| SCHEMBL30907435 | 0.81 | ABL1 (0.51) | ABL1MAP4K1 | |
| SCHEMBL30907120 | 0.80 | ABL1 (0.52) | ABL1MAP4K1 | |
| SCHEMBL30907100 | 0.80 | ABL1 (0.52) | ABL1MAP4K1 | |
| SCHEMBL30907308 | 0.80 | ABL1 (0.39) | ABL1 | |
| SCHEMBL30907294 | 0.79 | ABL1 (0.57) | GSK3BDYRK1AABL1 | |
| SCHEMBL30907451 | 0.78 | ABL1 (0.39) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024097953-A1 | NAPHTHYRIDINE COMPOUNDS FOR INHIBITION OF RAF KINASES | ENLIVEN INC. (US) | 2024-05-10 | — | — | WO | disclosed |